GS-US-352-4365 (#788)
Laufzeit: 01.01.2019 - 31.12.2040
Kurzfassung
Extended access of Momelotinib for subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Laufzeit: 01.01.2019 - 31.12.2040
Extended access of Momelotinib for subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
